Purpose To identify causes of symptomatic band keratopathy, and assess the results and long-term recurrence rates following chelation with topical ethylene-diamine-tetra-acetic acid (EDTA). Patients and methods A retrospective review of surgical logbooks identified patients managed by EDTA chelation for symptomatic band keratopathy from 2009 to 2015.
Introduction
Band keratopathy was first described by Dixon in 1848 as a degenerative condition of the cornea, characterised by deposition of grey-white opacities in the superficial corneal layers, most commonly in the exposed inter-palpebral region. 1, 2 It can be classified as primary or secondary, with a variety of predisposing systemic and ocular conditions, including renal failure, elevated serum calcium levels, chronic ocular inflammation, corneal ulcers, alkali chemical burns (and phosphate-based irrigating solutions), and a compromised ocular surface due to adverse reactions to preservatives/ buffers in ocular drops, particularly in patients on life-long therapy. [1] [2] [3] [4] [5] Familial band keratopathy has also been reported. 6 The natural history of band keratopathy is gradual progression over many months/years; however, there have been isolated reports of acute incidence following intra-cameral injection of tissue plasminogen activator to treat postoperative fibrinous reaction. 7, 8 In most cases band keratopathy is superficial. Histological analysis of affected corneas have revealed a selective, fine-granular calcification of Bowman's membrane, while other studies have reported deep-situated calcium plaques also involving the anterior stroma. 1, 2 In the early stages of the condition, the patients remain asymptomatic; however, extension into the visual axis can result in glare and reduced visual acuity. Furthermore, a breakdown of the ocular surface can result in painful recurrent corneal erosion-like symptoms and predispose to corneal ulceration. It is our recommendation that band keratopathy should only be removed when visually significant or causing ocular surface symptoms. (See Figure 1 for a range of clinical presentations).
Previous generations used mechanical debridement to remove superficial calcium deposition for the cornea. 9 The most popular current method involves the use of a metal ion chelator known as ethylene-diamine-tetra-acetic acid (EDTA). Studies have reported EDTA chelation to be a safe, reliable method of removing band keratopathy, resulting in improvements in visual acuity and ocular comfort. 1, 2 This procedure can be used in isolation or supplemented with superficial keratectomy (manual or excimer laser PTK) or amniotic membrane transplant. [10] [11] [12] [13] [14] A technique using alcohol to elevate and preserve the epithelium, use of EDTA and then replacement of the epithelial sheet similar to LASEK to provide better analgesia has also been described. 15 We wished to review the use of EDTA chelation in our department, assess the results and long-term recurrence rates following treatment, and identify the causes of symptomatic band keratopathy in our population.
Methods
We conducted a retrospective case note review of patients who underwent 'EDTA chelation' in a university hospital setting in Glasgow, UK, between 2009 and 2015. Inclusion criteria comprised any patients undergoing EDTA chelation to treat band keratopathy over the age of 18 years. Exclusion criteria included manual removal of calcium without EDTA, or use of adjuvant therapy such as amniotic membrane or conjunctival grafts.
Patient demographics included patient's age, laterality, diagnosis, presenting visual acuity (initial VA) and indication for EDTA chelation. The clinic visit closest to the 4 weeks post-operative review was evaluated for VA and clearance of visual axis. Long-term measures such as time to recurrence and subsequent retreatment were also investigated.
The improvement or worsening of VA was noted at 4-week follow-up and a change of two or more lines of Snellen VA was considered clinically significant. Visual acuity was not considered to have changed significantly if it remained within one line of initial VA. Statistical analysis involved use of a Wilcoxon signed rank test to assess change in VA and a Mann-Whitney test to evaluate if presenting or final median VA had a correlation with recurrence of band keratopathy.
The EDTA chelation procedure was as follows: After informed consent, topical anaesthetic was administered and a lid speculum inserted in theatre. A solution of 20% alcohol was applied to the cornea within a LASIK well for 40 s and the epithelium removed. EDTA (in the form of disodium edetate 0.37% eye drops) was applied to the surface for 3 min intervals and the loosened calcium deposits were debrided with a curved blade. A bandage contact lens was placed at the end of the procedure, and preservative-free dexamethasone 0.1% and chloramphenicol 0.5% drops were prescribed for the post- 
Results
A total of 108 cases of EDTA chelation were identified in the period 2009-2015. Of the 108 cases, 10 additionally had an amniotic membrane transplant while one had a conjunctival flap, so these 11 cases were excluded from the series. A further eight case notes were irretrievable. A total of 89 eyes from 72 patients were available for analysis. All patients underwent EDTA chelation by five different surgeons in NHS Greater Glasgow and Clyde, so these results are representative of a typical university hospital setting and population.
Demographics
There were 41 right eyes and 48 left eyes. The mean age was 71 years (range 18-93). Most cases of band keratopathy were idiopathic (36%, 32/89). The most common underlying diagnosis was long-term topical glaucoma therapy (27%). (See Table 1 for other causes.) The median presenting visual acuity was 6/18 (range 6/6-NPL) with the visual axis affected in 97.8% of cases.
The mean duration of the operation was 20 min (range 10-45); which involved corneal epithelium removal, recurrent application of topical EDTA, and mechanical debridement as previously detailed.
Outcomes
There were no documented surgical complications, although one case had a residual epithelial defect at 4 weeks follow-up, which subsequently healed. The mean initial follow-up time was 40 days. At follow-up, the visual axis was found to be clear in 97.8% of cases. Visual acuity was maintained or improved in 79.8%, with 13.5% improving by two lines or more (see Figure 3) . However, there was no evidence of a difference between the initial VA and final VA following treatment (Wilcoxon signed rank test P = 0.441).
Recurrence
The mean length of total follow-up was 581 days (median 374, maximum 2438). Twenty-five eyes (28.1%) showed localised recurrence of calcium with a mean time of 546 days (median 374), but only four cases (4.5% overall) Figure 2 Clinical picture demonstrating 0.37% disodium edetate. Figure 3 Graph showing changes in visual acuity following EDTA chelation of band keratopathy.
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Eye required repeat EDTA chelation. The median time between operations was 430 days. Of note, 32% of cases of recurrence were associated with hypotony or chronic presence of silicone oil, and 10 of the recurrent cases (40%) had an initial VA of less than 6/120. There was no evidence of a difference between the median initial VA values between those with and without recurrence (P = 0.843, Mann-Whitney), or between the median final VA values between those with and without recurrence (P = 0.288, Mann-Whitney) (see Figures 
Discussion
This large study of 89 treated eyes has documented the main causes of band keratopathy, and the effectiveness of EDTA chelation therapy with good long-term follow-up.
The previous largest review of band keratopathy in the published literature consisted of 65 treated eyes from Wills Eye Hospital, Philadelphia, USA in 2004. 2 In their series, they reported the most common cause of band keratopathy to be chronic corneal oedema (28%) followed by idiopathic (25.9%), then phthisis (16.4%). Although not all of their patients underwent EDTA surgical therapy (they identified 230 patients with band keratopathy, but only treated 65 eyes), the range of diagnoses bear similarity to our findings. 1, 2 The majority of our cases of band keratopathy needing EDTA chelation had no underlying local or systemic cause identified (idiopathic 36%). The most common cause we identified for band keratopathy was chronic topical glaucoma treatment (27%). Long-term use of topical medications (including active drug, preservatives, and excipients/buffers) have been implicated in the formation of band keratopathy in many studies, and particularly if the ocular surface is unhealthy. [16] [17] [18] [19] We have previously published on the potential detrimental impact of chronic excipient exposure in glaucoma patients, best considered to be a low grade 'lifelong chemical injury' related to the pH and chronic free radical damage from their ocular anti-hypertensives. 20, 21 Both superficial and deep band keratopathy have been linked with the presence of phosphate excipients in topical ophthalmic medications. 22 Popiela et al surveyed 78 commonly used ophthalmic medications for information regarding their excipients, and discovered that 22 of the drugs contained phosphates, and a further 43 drugs contained buffers (excipients) other than phosphates. 23 The European Medicines Agency has evaluated 117 possible or confirmed case reports of band keratopathy associated with use of phosphate-containing formulations and concluded that prescribers and patients should be aware of a potential causative link to calcification, particularly in those with ocular surface disease. 24 This warning has been added to the Summary of Product Characteristics, Section 4.8 (undesirable effects) for phosphate-based medicines.
Visual acuity was seen to be maintained or improved in 79.8% of our cases, with 13.5% improving by two lines or more. However, we were surprised to note that initial and final median visual acuity improvements did not reach statistical significance. This was particularly relevant for patients at the extremes of initial presenting vision, as sub-group analysis revealed that all 29 patients presenting with VA 6/9 or better, and all 22 patients presenting with initial VA less than 6/120 did not achieve an improvement of 2 or more Snellen lines. This observation replicates the published literature that those patients with 'sick eyes' are likely to have other ocular comorbidities causing the poor vision, and therefore treatment should be planned for comfort rather than vision. 1, 2 Consistent with this, 80% of those patients with counting fingers or worse vision reported improved ocular surface comfort following treatment.
In our series, 28.9% (11/38) of cases with initial visual acuity from 6/12 to 6/120 had a clinically significant 
